Vivos Therapeutics (NASDAQ:VVOS) Stock Price Down 3.5%

Vivos Therapeutics, Inc. (NASDAQ:VVOSGet Rating)’s stock price fell 3.5% on Monday . The company traded as low as $1.37 and last traded at $1.37. 10,379 shares changed hands during trading, a decline of 99% from the average session volume of 1,010,113 shares. The stock had previously closed at $1.42.

Analyst Upgrades and Downgrades

Separately, Craig Hallum lowered their price objective on shares of Vivos Therapeutics to $5.00 and set a “na” rating for the company in a research report on Tuesday, May 17th.

Vivos Therapeutics Trading Down 3.5 %

The company has a market cap of $31.53 million, a PE ratio of -1.30 and a beta of 1.42. The company’s 50 day moving average is $1.48 and its 200 day moving average is $2.05.

Vivos Therapeutics (NASDAQ:VVOSGet Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $3.46 million for the quarter, compared to analysts’ expectations of $4.50 million. Analysts expect that Vivos Therapeutics, Inc. will post -1 EPS for the current year.

Institutional Trading of Vivos Therapeutics

A number of institutional investors have recently modified their holdings of VVOS. Renaissance Technologies LLC bought a new stake in shares of Vivos Therapeutics in the 1st quarter valued at about $29,000. Cambridge Investment Research Advisors Inc. boosted its stake in Vivos Therapeutics by 60.0% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 19,200 shares of the company’s stock worth $43,000 after purchasing an additional 7,200 shares in the last quarter. State Street Corp boosted its stake in Vivos Therapeutics by 150.4% in the 1st quarter. State Street Corp now owns 45,650 shares of the company’s stock worth $122,000 after purchasing an additional 27,417 shares in the last quarter. National Asset Management Inc. boosted its stake in Vivos Therapeutics by 55.5% in the 4th quarter. National Asset Management Inc. now owns 79,270 shares of the company’s stock worth $179,000 after purchasing an additional 28,283 shares in the last quarter. Finally, Griffin Asset Management Inc. boosted its stake in Vivos Therapeutics by 63.3% in the 1st quarter. Griffin Asset Management Inc. now owns 70,200 shares of the company’s stock worth $188,000 after purchasing an additional 27,200 shares in the last quarter. 9.81% of the stock is currently owned by institutional investors.

Vivos Therapeutics Company Profile

(Get Rating)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

See Also

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.